可治愈性胃食管癌治疗分配与生存的性别差异:一项基于人群的研究
该全国性队列研究纳入2006至2018年荷兰癌症登记处27,496例可治愈性胃食管鳞癌或腺癌患者(68.8%为男性),比较男女治疗分配与5年相对生存。年轻(≤70岁)胃食管腺癌患者男女治愈性治疗率相当,但老年女性食管腺癌患者接受治愈性治疗的概率低于男性(OR=0.85,95%CI 0.73-0.99)。接受治愈性治疗者中,女性食管腺癌(RER=0.88,95%CI 0.80-0.96)和食管鳞癌(RER=0.82,95%CI 0.75-0.91)相对生存优于男性,胃腺癌男女相当(RER=1.02,95%CI 0.94-1.11)。
要点
- 27,496例可治愈性胃食管癌患者中,68.8%为男性,62.8%接受治愈性治疗,>70岁者降至45.6%。
- ≤70岁胃食管腺癌男女治愈性治疗率相当;老年女性食管腺癌接受治愈性治疗少于男性(OR=0.85,95%CI 0.73-0.99)。
- 接受治愈性治疗者中,女性食管腺癌(RER=0.88,95%CI 0.80-0.96)和食管鳞癌(RER=0.82,95%CI 0.75-0.91)相对生存优于男性。
核心结论
- 年轻(≤70岁)男女性胃食管腺癌患者治愈性治疗率相当,但老年患者存在治疗差异。
- 接受治疗时,女性食管腺癌和食管鳞癌患者生存优于男性。
- 男女胃食管癌患者间的治疗与生存差距需进一步探索,可能改善治疗策略与生存。
研究设计与样本
- 全国性队列研究,纳入2006至2018年荷兰癌症登记处登记的所有可治愈性胃食管鳞癌或腺癌患者,共27,496例(68.8%为男性)。
主要发现
- 62.8%的患者接受治愈性治疗,>70岁者降至45.6%。
- ≤70岁胃食管腺癌男女治愈性治疗率相当;老年女性食管腺癌接受治愈性治疗少于男性(OR=0.85,95%CI 0.73-0.99)。
- 接受治愈性治疗者中,女性食管腺癌相对生存优于男性(RER=0.88,95%CI 0.80-0.96)。
- 接受治愈性治疗者中,女性食管鳞癌相对生存优于男性(RER=0.82,95%CI 0.75-0.91)。
- 接受治愈性治疗者中,胃腺癌男女相对生存相当(RER=1.02,95%CI 0.94-1.11)。
关键数值与推荐
- 治愈性治疗率总体为62.8%,>70岁患者为45.6%。
- 老年女性食管腺癌接受治愈性治疗 vs 男性:OR=0.85(95%CI 0.73-0.99)。
- 女性食管腺癌相对生存 vs 男性:RER=0.88(95%CI 0.80-0.96)。
- 女性食管鳞癌相对生存 vs 男性:RER=0.82(95%CI 0.75-0.91)。
- 胃腺癌男女相对生存比较:RER=1.02(95%CI 0.94-1.11)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although curative treatment options are identical for male and female gastroesophageal cancer patients, access to care and survival may vary. This study aimed to compare treatment allocation and survival between male and female patients with potentially curable gastroesophageal cancer. METHODS: Nationwide cohort study including all patients with potentially curable gastroesophageal squamous cell or adenocarcinoma diagnosed between 2006 and 2018 registered in the Netherlands Cancer Registry. The main outcome, treatment allocation, was compared between male and female patients with oesophageal adenocarcinoma (EAC), oesophageal squamous cell carcinoma (ESCC), and gastric adenocarcinoma (GAC). Additionally, 5-year relative survival with relative excess risk (RER), that is, adjusted for the normal life expectancy, was compared. RESULTS: Among 27,496 patients (68.8% men), most were allocated to curative treatment (62.8%), although rates dropped to 45.6%>70 years. Curative treatment rates were comparable among younger male and female patients (≤70 years) with gastroesophageal adenocarcinoma, while older females with EAC were less frequently allocated to curative treatment than males (OR = 0.85, 95% confidence interval [CI] 0.73-0.99). For those allocated to curative treatment, relative survival was superior for female patients with EAC (RER = 0.88, 95% CI 0.80-0.96) and ESCC (RER = 0.82, 95% CI 0.75-0.91), and comparable for males and females with GAC (RER = 1.02, 95% CI 0.94-1.11). CONCLUSIONS: While curative treatment rates were comparable between younger male and female patients with gastroesophageal adenocarcinoma, treatment disparities were present between older patients. When treated, the survival of females with EAC and ESCC was superior to males. The treatment and survival gaps between male and female patients with gastroesophageal cancer warrant further exploration and could potentially improve treatment strategies and survival.
引用
- Kalff MC, Dijksterhuis WPM, Wagner AD, et al. Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study. Eur J Cancer. 2023. PMID: 37146505. doi:10.1016/j.ejca.2023.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。